JP2016501877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501877A5 JP2016501877A5 JP2015545481A JP2015545481A JP2016501877A5 JP 2016501877 A5 JP2016501877 A5 JP 2016501877A5 JP 2015545481 A JP2015545481 A JP 2015545481A JP 2015545481 A JP2015545481 A JP 2015545481A JP 2016501877 A5 JP2016501877 A5 JP 2016501877A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding portion
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000427 antigen Substances 0.000 claims 27
- 102000036639 antigens Human genes 0.000 claims 27
- 108091007433 antigens Proteins 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 239000003053 toxin Substances 0.000 claims 13
- 231100000765 toxin Toxicity 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241000193163 Clostridioides difficile Species 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- RBORURQQJIQWBS-QVRNUERCSA-N (4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-hydroxy-2-sulfanylidene-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound C([C@H]1O2)OP(O)(=S)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br RBORURQQJIQWBS-QVRNUERCSA-N 0.000 claims 1
- 241000261561 Bembidion difficile Species 0.000 claims 1
- 101001055311 Equus asinus Immunoglobulin heavy constant alpha Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730790P | 2012-11-28 | 2012-11-28 | |
| US61/730,790 | 2012-11-28 | ||
| PCT/US2013/072467 WO2014085749A2 (en) | 2012-11-28 | 2013-11-29 | Antibodies against clostridium difficile |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501877A JP2016501877A (ja) | 2016-01-21 |
| JP2016501877A5 true JP2016501877A5 (2) | 2017-01-12 |
Family
ID=50828602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545481A Ceased JP2016501877A (ja) | 2012-11-28 | 2013-11-29 | クロストリジウム・ディフィシルに対する抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10117933B2 (2) |
| EP (1) | EP2925362A4 (2) |
| JP (1) | JP2016501877A (2) |
| CN (2) | CN109776676A (2) |
| AU (2) | AU2013352034B2 (2) |
| CA (1) | CA2892973A1 (2) |
| HK (1) | HK1216999A1 (2) |
| IL (1) | IL239063A0 (2) |
| WO (1) | WO2014085749A2 (2) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| CN109776676A (zh) * | 2012-11-28 | 2019-05-21 | Cnj控股公司 | 针对艰难梭菌的抗体 |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| EP4168032A2 (en) | 2020-06-19 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| USD952157S1 (en) | 2020-06-19 | 2022-05-17 | Qualigen Inc. | Whole blood treatment cartridge |
| EP4232818A1 (en) * | 2020-10-20 | 2023-08-30 | Fzata, Inc. | Neutralized antibody and method of use thereof |
| CN112812189B (zh) * | 2020-11-30 | 2022-05-17 | 四川大学华西医院 | 一种抗糖基转移酶a亚单位的纳米抗体及其应用 |
| US20250059267A1 (en) * | 2021-05-14 | 2025-02-20 | Phenomic Ai | Combination therapy for treatment of tumors comprising cancer-associated fibroblasts |
| CN116239683B (zh) * | 2023-02-15 | 2024-12-27 | 兰州生物制品研究所有限责任公司 | 一种抗艰难梭菌毒素b的单克隆抗体及其制备方法和应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5332583A (en) | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
| US5221618A (en) | 1987-11-24 | 1993-06-22 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5244657A (en) | 1987-11-24 | 1993-09-14 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5435945A (en) | 1992-05-29 | 1995-07-25 | Procor Sulphur Services, Inc. | Method and apparatus for generating sulphur seed particles for sulphur granule production |
| DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
| CA2398466A1 (en) | 2000-01-27 | 2001-08-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
| EP1532175B1 (en) | 2002-03-22 | 2012-10-17 | Aprogen, Inc. | Humanized antibody and process for preparing the same |
| AU2003299527A1 (en) * | 2002-06-17 | 2004-06-07 | Jimmy D. Ballard | Mutant of clostridium difficile toxin b and methods of use |
| GB0309126D0 (en) * | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| WO2005035575A2 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| LT2857418T (lt) * | 2004-02-06 | 2017-09-25 | University Of Massachusetts | Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| WO2007065037A2 (en) | 2005-12-02 | 2007-06-07 | Curagen Corporation | Antibodies against mmp-13 (collagenase-3) and uses thereof |
| BRPI0720565A2 (pt) | 2006-12-20 | 2013-09-17 | Mmr Information Systems Inc | anticorpos e mÉtodos para a sua preparaÇço e seu uso |
| WO2009108652A1 (en) * | 2008-02-28 | 2009-09-03 | 3M Innovative Properties Company | Antibodies to clostridium difficile spores and uses thereof |
| US8709428B2 (en) * | 2009-02-20 | 2014-04-29 | Health Protection Agency | Antibodies to Clostridium difficile toxins |
| US20120282274A1 (en) * | 2009-11-20 | 2012-11-08 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment |
| KR101820987B1 (ko) * | 2010-04-15 | 2018-01-22 | 프로제닉스 파머슈티컬스, 인코포레이티드 | 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체 |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| CA2815888C (en) * | 2010-10-25 | 2020-06-30 | National Research Council Of Canada | Clostridium difficile-specific antibodies and uses thereof |
| WO2012092469A2 (en) * | 2010-12-29 | 2012-07-05 | Cangene Corporation | Clostridium difficile antigens |
| US9815889B2 (en) * | 2011-08-02 | 2017-11-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Antibodies for prevention and treatment of diseases caused by clostridium difficile |
| US9505847B2 (en) * | 2011-08-22 | 2016-11-29 | Cnj Holdings Inc | Clostridium difficile antibodies |
| SG10201701055WA (en) * | 2011-09-16 | 2017-03-30 | Ucb Pharma Sa | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
| DE102011121238A1 (de) * | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-antikörper gegen clostridium difficile toxine |
| WO2014061783A1 (ja) * | 2012-10-19 | 2014-04-24 | 株式会社イーベック | クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片 |
| CN109776676A (zh) * | 2012-11-28 | 2019-05-21 | Cnj控股公司 | 针对艰难梭菌的抗体 |
| EP4079760A3 (en) * | 2013-03-15 | 2023-01-25 | Sanofi Pasteur Inc. | Antibodies against clostridium difficile toxins and methods of using the same |
| EP2957570B1 (en) * | 2014-06-20 | 2019-04-17 | Immunimed Inc. | Polyclonal antibodies against clostridium difficile and uses thereof |
| US11434264B2 (en) * | 2015-02-13 | 2022-09-06 | Quanterix Corporation | Immunoassays for differential detection of clostridium difficile |
| HK1250167A1 (zh) * | 2015-02-19 | 2018-11-30 | 免疫生物进化公司 | 艰难梭菌毒素a和/或b抗原和表位抗体及其药学用途 |
-
2013
- 2013-11-29 CN CN201811406032.6A patent/CN109776676A/zh active Pending
- 2013-11-29 HK HK16105037.6A patent/HK1216999A1/zh unknown
- 2013-11-29 US US14/648,234 patent/US10117933B2/en active Active
- 2013-11-29 AU AU2013352034A patent/AU2013352034B2/en not_active Ceased
- 2013-11-29 CN CN201380071593.4A patent/CN105025926B/zh not_active Expired - Fee Related
- 2013-11-29 CA CA2892973A patent/CA2892973A1/en not_active Abandoned
- 2013-11-29 JP JP2015545481A patent/JP2016501877A/ja not_active Ceased
- 2013-11-29 EP EP13857740.8A patent/EP2925362A4/en not_active Withdrawn
- 2013-11-29 WO PCT/US2013/072467 patent/WO2014085749A2/en not_active Ceased
-
2015
- 2015-05-28 IL IL239063A patent/IL239063A0/en unknown
-
2018
- 2018-10-29 AU AU2018256482A patent/AU2018256482A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501877A5 (2) | ||
| JP2023002706A (ja) | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 | |
| JP2014529610A5 (2) | ||
| JP2017535257A5 (2) | ||
| JP2018512138A5 (2) | ||
| US12247075B2 (en) | BTN3A binding proteins and uses thereof | |
| JP2014511179A5 (2) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2009225799A5 (2) | ||
| JP2018532383A5 (2) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2013506428A5 (2) | ||
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| JP2018502060A5 (2) | ||
| JP2010536384A5 (2) | ||
| JP2012518425A5 (2) | ||
| JP2015503909A5 (2) | ||
| HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
| TW201134487A (en) | Therapeutic DLL4 binding proteins | |
| JP2011207882A5 (2) | ||
| CN114729053B (zh) | 一种4-1bb结合蛋白及其应用 | |
| JP2013519364A5 (2) | ||
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| JP2017507131A5 (2) |